# Phase 3 Leukemia, Myeloid, Acute trials: 42 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials in phase 3 for Leukemia, Myeloid, Acute that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Leukemia, Myeloid, Acute trials: 42 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/leukemia-myeloid-acute

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 42
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925190 | A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Recruiting | Acute Myeloblastic Leukemia | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925190) |
| August 12, 2026 | NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | Shanghai Jiao Tong University School of Medicine | Phase 3 | Not yet recruiting | AML (Acute Myelogenous Leukemia) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761702) |
| July 29, 2026 | NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | Ruijin Hospital | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735117) |
| July 20, 2026 | NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | The Second Affiliated Hospital of Kunming Medical University | Phase 3 | Recruiting | AML (Acute Myeloid Leukemia) | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712848) |
| July 7, 2026 | NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at... | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Maintenance Treatment, Hematopoetic Stem Cell Transplantation | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686965) |
| April 7, 2026 | NCT07514936 | Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | Chinese PLA General Hospital | Phase 3 | Recruiting | Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514936) |
| March 20, 2026 | NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | The First Affiliated Hospital of Soochow University | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486479) |
| March 18, 2026 | NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | PETHEMA Foundation | Phase 3 | Recruiting | Acute Myeloid Leukemia, Adult | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478991) |
| March 13, 2026 | NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years) | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469046) |
| March 11, 2026 | NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | The First Affiliated Hospital of Soochow University | Phase 3 | Recruiting | Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance... | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463651) |
| February 12, 2026 | NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With... | Peking University People's Hospital | Phase 3 | Not yet recruiting | Acute Myeloid Leukemia | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407660) |
| February 12, 2026 | NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | AML, Adult | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407140) |
| November 18, 2025 | NCT07232134 | The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | Recruiting | AML (Acute Myelogenous Leukemia), Down Syndrome (DS) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07232134) |
| November 3, 2025 | NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute... | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | Recruiting | Acute Myeloid Leukemia | 875 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223814) |
| October 8, 2025 | NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Syndax Pharmaceuticals | Phase 3 | Recruiting | Acute Myeloid Leukemias | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211958) |
| August 20, 2025 | NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Recruiting | AML, Adult | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07132684) |
| July 24, 2025 | NCT07082452 | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | Not yet recruiting | Leukemia, B-Cell, Chronic, Leukemia | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082452) |
| July 20, 2025 | NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered... | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | Recruiting | Acute Myeloid Leukemia | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07075016) |
| June 15, 2025 | NCT07022678 | Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Children's Oncology Group | Phase 3 | Recruiting | Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022678) |
| June 5, 2025 | NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Kura Oncology, Inc. | Phase 3 | Recruiting | Acute Myeloid Leukemia (AML) | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007312) |
| May 25, 2025 | NCT06990321 | Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Acute Myeloid Leukemia (AML), Elderly | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06990321) |
| February 28, 2025 | NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Janssen Research & Development, LLC | Phase 3 | Recruiting | Leukemia, Myeloid, Acute | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06852222) |
| February 17, 2025 | NCT06829472 | Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan | Shanghai Jiao Tong University School of Medicine | Phase 3 | Recruiting | Toxicities, Survivorship | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829472) |
| February 6, 2025 | NCT06810791 | HVA vs IA/DA or VA in the Treatment of ND HR-AML | Nanfang Hospital, Southern Medical University | Phase 3 | Recruiting | Newly Diagnosed Acute Myeloid Leukemia With High Risk | 876 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810791) |
| January 31, 2025 | NCT06802718 | Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | Peking University People's Hospital | Phase 3 | Recruiting | Acute Myeloid Leukemia | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06802718) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Shanghai Jiao Tong University School of Medicine | 3 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 3 |
| Children's Oncology Group | 2 |
| Peking University People's Hospital | 2 |
| Ruijin Hospital | 2 |
| The First Affiliated Hospital of Soochow University | 2 |
| [Sunshine Lake Pharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-lake-pharma-co-ltd) | 1 |
| Chinese PLA General Hospital | 1 |
| National Research Center for Hematology, Russia | 1 |
| Vastra Gotaland Region | 1 |
| University of Ulm | 1 |
| The Second Affiliated Hospital of Kunming Medical University | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| Servier Affaires Médicales | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| PETHEMA Foundation | 1 |
| [Hutchmed](https://specstream.ai/data/clinical-trials/company/hutchmed) | 1 |
| [Syndax Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/syndax-pharmaceuticals) | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Kura Oncology, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 19 |
| Spain | 10 |
| Germany | 9 |
| Italy | 9 |
| Belgium | 8 |
| France | 8 |
| United States | 8 |
| Austria | 7 |
| Lithuania | 6 |
| Netherlands | 6 |
| Australia | 6 |
| United Kingdom | 6 |
| Finland | 5 |
| Norway | 5 |
| Denmark | 4 |
| Israel | 4 |
| Sweden | 4 |
| Estonia | 4 |
| Switzerland | 4 |
| Canada | 4 |
| Poland | 4 |
| Russia | 3 |
| Brazil | 3 |
| Greece | 3 |
| Hungary | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
- [Colleges and universities in the United States](https://specstream.ai/data/businesses/colleges-and-universities/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
